In addition to erlotinib, the ongoing ALCHEMIST study is evaluating the utility of crizotinib (ALK inhibitor) and nivolumab (PD1 inhibitor) in completely resected NSCLC post standard care adjuvant therapy. The gene discussed is ALK; the disease is non-small cell lung carcinoma.